CAVEAT mTOR: You’ve heard about the benefits of using mTOR inhibitors, here are some of the risks

Eisen reviews Asleh et al.'s article (page 626) that shows that the development of significant proteinuria after conversion to mTOR‐ based immunosuppression is a harbinger of poor outcomes for cardiac transplant recipients.

Saved in:
Bibliographic Details
Published inAmerican journal of transplantation Vol. 21; no. 2; pp. 449 - 450
Main Author Eisen, Howard J.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.02.2021
Subjects
Allografts
Clinical outcomes
clinical research/practice
Heart Transplantation
heart transplantation/cardiology
Heart transplants
Humans
immunosuppressant ‐ mechanistic target of rapamycin: sirolimus
Immunosuppression
immunosuppression/immune modulation
Inhibitor drugs
kidney (native) function/dysfunction
Proteinuria
TOR protein
TOR Serine-Threonine Kinases
vasculopathy
immunosuppressant - mechanistic target of rapamycin: sirolimus
kidney (native) function/dysfunction
heart transplantation/cardiology
vasculopathy
immunosuppression/immune modulation
clinical research/practice
Online AccessGet full text

Cover

More Information
Summary:Eisen reviews Asleh et al.'s article (page 626) that shows that the development of significant proteinuria after conversion to mTOR‐ based immunosuppression is a harbinger of poor outcomes for cardiac transplant recipients.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1600-6135
1600-6143
DOI:10.1111/ajt.16225